Rigerna
Fengtai
About Rigerna
Rigerna develops unique small nucleic acid medicines and innovative nucleic acid therapies for nonliver tissues.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $43.1M
- Funding stage: Seed
- Last round: Seed (Mar 2026)
- Website: rigerna.comen
- Phone: [email protected]
Industries & Categories
Biopharma, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/rigerna-20882 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.